PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Net Receivables Growth compared to TRVN's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x TRVN's -23.50%. Michael Burry might investigate for potential short-term asset misclassification or risk.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
≥ 1.5x TRVN's -5.92%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
≥ 1.5x TRVN's -9.34%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
100.00%
Higher Other Assets Growth compared to TRVN's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-99.84%
Above 1.5x TRVN's -18.90%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-100.00%
Above 1.5x TRVN's -15.86%. Michael Burry sees a major discrepancy in short-term leverage. Check coverage and liquidity carefully.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Higher Deferred Revenue (Current) Growth compared to TRVN's zero value, indicating better performance.
100.00%
Similar yoy changes to TRVN's 100.00%. Walter Schloss finds parallel near-term liability trends.
13.77%
Similar yoy to TRVN's 16.90%. Walter Schloss sees parallel short-term liability strategies.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.32%
Less than half of TRVN's -0.77%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
11.40%
Above 1.5x TRVN's 1.42%. Michael Burry sees a potential leverage warning sign.
No Data
No Data available this quarter, please select a different quarter.
-3.71%
≥ 1.5x TRVN's -0.82%. David Dodd sees higher yoy retained profits than competitor.
No Data
No Data available this quarter, please select a different quarter.
110.36%
Higher Other Stockholders' Equity Items Growth compared to TRVN's zero value, indicating worse performance.
-11.42%
Below half TRVN's -22.96%. Michael Burry sees potential underperformance in building shareholder capital.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.32%
Less than half of TRVN's -94.51%. David Dodd sees less overall debt expansion vs. competitor.
10.35%
Less than half of TRVN's -156.99%. David Dodd sees better deleveraging or stronger cash buildup than competitor.